GlobeNewswire Inc.··NaApellis to Highlight Complement Science Portfolio at TD Cowen Healthcare Forum
Apellis will discuss its complement-targeted drug portfolio at TD Cowen Healthcare Forum in March 2026, highlighting its approved therapies for eye and kidney diseases.
APLSbiopharmaceuticalApellis Pharmaceuticals